Merck signs up to $3.3 bln cancer drug deal with China-based ...
15 hours ago · Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, make and sell an experimental cancer drug, the two companies said on Thursday.
Merck Snags Chinese Cancer Drug in Deal Worth Up to $3.3 ...
15 hours ago · Merck & Co. licensed an experimental cancer antibody from a closely held Chinese company in a deal worth $588 million upfront, plus as much as $2.7 billion in milestone payments.
News releases - Merck.com
Oct 28, 2024 · Merck Announces Third-Quarter 2024 Financial Results. October 28, 2024. Merck and Moderna Initiate Phase 3 Trial Evaluating Adjuvant V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) After Neoadjuvant KEYTRUDA and Chemotherapy in Patients With Certain Types of Non-Small Cell Lung Cancer (NSCLC) October 24, 2024.
Merck Enters into Exclusive Global License for LM-299, An ...
15 hours ago · Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and LaNova Medicines Ltd. (LaNova), a privately held clinical-stage biotechnology company, today announced that Merck has entered into an exclusive global license to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova. “At Merck, we continue to assemble a ...
Merck KGaA Earnings Growth Beats Expectations — Update
19 hours ago · Merck now expects 2024 net sales in the lower half of its previously expected range of 20.7 billion to 22.1 billion euros. On an organic basis, sales rose across segments. Healthcare sales rose 6. ...
FDA Approves Merck’s WINREVAIR™ (sotatercept-csrk), a First ...
Mar 26, 2024 · WINREVAIR is the first FDA-approved activin signaling inhibitor therapy for PAH, representing a new class of therapy that works by improving the balance between pro- and anti-proliferative signaling to regulate vascular cell proliferation underlying PAH. WINREVAIR logo (Graphic: Merck & Co., Inc.)
News & Stories - Merck
Oct 9, 2024 · Check out the latest Merck news and stories! Learn more about the leading science and technology company here.
Merck Expands Oncology Pipeline By Securing License For ...
14 hours ago · Nov. 14, 2024, 07:27 AM. (RTTNews) - Merck & Co Inc. (MRK) and LaNova Medicines Ltd., a privately held clinical-stage biotechnology company Thursday said Merck has secured global license to ...
Merck raises 2024 profit forecast on surging sales of cancer ...
Apr 25, 2024 · Merck & Co on Thursday raised its annual profit and revenue forecasts on the back of double-digit growth for its blockbuster cancer drug Keytruda, the world's top selling prescription medicine.
Merck KGaA Expects Sales at Lower End of Outlook Range After ...
20 hours ago · Germany’s Merck MRK 0.43% KGaA expects annual sales to be at the lower half of its outlook range after third-quarter sales missed expectations. The life-sciences and chemical group said Thursday ...